The present invention relates to a method for the treatment of psoriasis comprising administering to a subject suffering from moderate to severe psoriasis 2 mg of 1- [N 6 - (3-iodobenzyl) -adenine-9-yl] -? - D- ribofuronamide (IB- Total daily dose) is twice as effective in the treatment of psoriatic plaques than psoriasis in a two-dose dose of 1 mg or 4 mg (total daily dose of 2 or 8 mg, respectively) It is based on the result of enemy investigation. Accordingly, the present invention provides a pharmaceutical composition for the treatment of psoriasis, comprising IB-MECA as an active ingredient in an amount sufficient to administer a total daily dose of about 4 mg. In one preferred embodiment, the IB-MECA is administered twice daily to a subject in need of psoriasis treatment, and the pharmaceutical composition comprises a dose of 2 mg.
展开▼
